Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec 1;34(12):2051-2052.
doi: 10.1681/ASN.0000000000000230.

Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?

Jun-Zhang Chen  1 , Bo Liang  2
Affiliations
Comment

Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?

Jun-Zhang Chen et al. J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors have nothing to disclose.

Comment in

Comment on

References

    1. Perico N Remuzzi G Griffin MD, et al. . Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733–1751. doi:10.1681/ASN.0000000000000189 - DOI - PMC - PubMed
    1. Perico N, Casiraghi F, Remuzzi G. Clinical translation of mesenchymal stromal cell therapies in nephrology. J Am Soc Nephrol. 2018;29(2):362–375. doi:10.1681/ASN.2017070781 - DOI - PMC - PubMed
    1. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol. 1993;3(8):1458–1466. doi:10.1681/ASN.V381458 - DOI - PubMed
    1. Ohta H, Liu X, Maeda M. Autologous adipose mesenchymal stem cell administration in arteriosclerosis and potential for anti-aging application: a retrospective cohort study. Stem Cell Res Ther. 2020;11(1):538. doi:10.1186/s13287-020-02067-x - DOI - PMC - PubMed

LinkOut - more resources